Immunome Inc.
Clinical-stage oncology company developing Antibody-Drug Conjugates and Radioligand Therapies.
IMNM | US
Overview
Corporate Details
- ISIN(s):
- US45257U1088
- LEI:
- Country:
- United States of America
- Address:
- 18702 N. CREEK PARKWAY, 98011 BOTHELL
- Website:
- https://immunome.com/
- Sector:
- Manufacturing
Description
Immunome Inc. is a clinical-stage oncology company focused on developing targeted therapies to improve outcomes for cancer patients. The company specializes in creating first-in-class and best-in-class therapeutic candidates, with a primary focus on Antibody-Drug Conjugates (ADCs) and Radioligand Therapies (RLTs). Immunome utilizes a systematic, data-driven process to optimize each component of its drug candidates—antibody, linker, and payload—to address high unmet medical needs. Its clinical pipeline includes varegacestat, a gamma secretase inhibitor in a Phase 3 trial for desmoid tumors; IM-1021, a ROR1-targeted ADC in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand. The company also advances a portfolio of preclinical ADCs targeting various solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Immunome Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Immunome Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Immunome Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
